CN101365708B - 1-苯甲酰基-4-[2-[4-甲氧基-7-(3-甲基-1h-1,2,4-三唑-1-基)-1-[(膦酰氧基)甲基]-1h-吡唑并[2,3-c]吡啶-3-基]-1,2-二氧代乙基]-哌嗪的结晶形式 - Google Patents

1-苯甲酰基-4-[2-[4-甲氧基-7-(3-甲基-1h-1,2,4-三唑-1-基)-1-[(膦酰氧基)甲基]-1h-吡唑并[2,3-c]吡啶-3-基]-1,2-二氧代乙基]-哌嗪的结晶形式 Download PDF

Info

Publication number
CN101365708B
CN101365708B CN2006800472167A CN200680047216A CN101365708B CN 101365708 B CN101365708 B CN 101365708B CN 2006800472167 A CN2006800472167 A CN 2006800472167A CN 200680047216 A CN200680047216 A CN 200680047216A CN 101365708 B CN101365708 B CN 101365708B
Authority
CN
China
Prior art keywords
compound
crystallized form
methyl
fact
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800472167A
Other languages
English (en)
Chinese (zh)
Other versions
CN101365708A (zh
Inventor
陈中冰
道恩·迪朱尼奥
高琦
谷崇辉
亚夸·卡拉尼·莱翁斯
杨秉修
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
ViiV Healthcare UK No 4 Ltd
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101365708A publication Critical patent/CN101365708A/zh
Application granted granted Critical
Publication of CN101365708B publication Critical patent/CN101365708B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2006800472167A 2005-12-14 2006-12-13 1-苯甲酰基-4-[2-[4-甲氧基-7-(3-甲基-1h-1,2,4-三唑-1-基)-1-[(膦酰氧基)甲基]-1h-吡唑并[2,3-c]吡啶-3-基]-1,2-二氧代乙基]-哌嗪的结晶形式 Active CN101365708B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75024705P 2005-12-14 2005-12-14
US60/750,247 2005-12-14
PCT/US2006/047571 WO2007070589A2 (en) 2005-12-14 2006-12-13 Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine

Publications (2)

Publication Number Publication Date
CN101365708A CN101365708A (zh) 2009-02-11
CN101365708B true CN101365708B (zh) 2012-12-12

Family

ID=38163502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800472167A Active CN101365708B (zh) 2005-12-14 2006-12-13 1-苯甲酰基-4-[2-[4-甲氧基-7-(3-甲基-1h-1,2,4-三唑-1-基)-1-[(膦酰氧基)甲基]-1h-吡唑并[2,3-c]吡啶-3-基]-1,2-二氧代乙基]-哌嗪的结晶形式

Country Status (17)

Country Link
US (1) US7851476B2 (enExample)
EP (1) EP1963342A2 (enExample)
JP (1) JP5400387B2 (enExample)
KR (1) KR20080077010A (enExample)
CN (1) CN101365708B (enExample)
AU (1) AU2006326432B2 (enExample)
BR (1) BRPI0619851A2 (enExample)
CA (1) CA2635717A1 (enExample)
EA (1) EA014706B1 (enExample)
GE (1) GEP20125413B (enExample)
IL (1) IL191769A (enExample)
MY (1) MY144293A (enExample)
NO (1) NO20082477L (enExample)
NZ (2) NZ592684A (enExample)
UA (1) UA94928C2 (enExample)
WO (1) WO2007070589A2 (enExample)
ZA (1) ZA200805063B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
WO2009158394A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
ES2389478T3 (es) * 2008-06-25 2012-10-26 Bristol-Myers Squibb Company Derivados de dicetopiperidina como inhibidores de la fijación del VIH
US20100056540A1 (en) * 2008-09-04 2010-03-04 Bristol-Myers Squibb Company Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor
EP2646439B1 (en) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
CN103339130B (zh) * 2011-01-31 2015-05-06 百时美施贵宝公司 制备hiv附着抑制剂前药化合物的方法及中间体
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
EP2751118B1 (en) 2011-08-29 2016-10-12 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
EP2895471B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Piperidine amide derivatives as hiv attachment inhibitors
US9655888B2 (en) 2012-08-09 2017-05-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
RU2663466C1 (ru) * 2017-03-20 2018-08-06 Общество с ограниченной ответственностью "МБА-групп" Композиция для профилактики и/или лечения вич-инфекции
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
KR20250057081A (ko) 2019-04-24 2025-04-28 엘랑코 유에스 인코포레이티드 7h-피롤로[2,3-d]피리미딘 jak-억제제
CA3138234A1 (en) 2019-04-30 2020-11-05 Beijing Tide Pharmaceutical Co., Ltd. Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
WO2020244612A1 (zh) 2019-06-06 2020-12-10 劲方医药科技(上海)有限公司 Cdk9抑制剂的多晶型物及其制法和用途
US11306061B2 (en) 2019-07-08 2022-04-19 Rezolute, Inc. Crystalline forms of plasma kallikrein inhibitors
AU2020325416B2 (en) 2019-08-06 2025-08-21 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystalline form of ATR inhibitor and use thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (enExample) * 1959-09-25 1900-01-01
GB8615562D0 (en) * 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
IL99843A0 (en) 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors
US5811432A (en) * 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
AU653855B2 (en) 1991-07-03 1994-10-13 Pharmacia & Upjohn Company Indolyl carbonyl pyridinyl-poperazine/piperidine derivatives
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IT1265057B1 (it) 1993-08-05 1996-10-28 Dompe Spa Tropil 7-azaindolil-3-carbossiamidi
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9600559D0 (en) 1996-01-11 1996-03-13 British Biotech Pharm Use of chemokines
ATE234298T1 (de) * 1996-08-29 2003-03-15 Takeda Chemical Industries Ltd Zyklische etherverbindungen als natriumkanal- modulatoren
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
WO1999024065A1 (en) 1997-11-10 1999-05-20 The Trustees Of Columbia University In The City Of New York COMPOUNDS INHIBITING CD4-gp120 INTERACTION AND USES THEREOF
NZ506435A (en) 1998-03-26 2002-08-28 Shionogi & Co 3-Indoly-2-hydroxy-4-oxo-2-butanoic acid useful as antiviral activity
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE69934311D1 (de) 1998-06-30 2007-01-18 Lilly Co Eli BICYCLISCHE sPLA 2-INHIBITOREN
JP2002523448A (ja) 1998-08-28 2002-07-30 サイオス インコーポレイテッド ｐ３８−αキナーゼのインヒビター
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2000071535A1 (en) 1999-05-21 2000-11-30 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
JP2004502768A (ja) 2000-07-10 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー 置換インドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性
US6573262B2 (en) * 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
KR20030079979A (ko) 2001-02-02 2003-10-10 브리스톨-마이어스스퀴브컴파니 치환된 아자인돌옥소아세틱 피페라진 유도체의 조성물 및항바이러스 활성
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
EP1453515A4 (en) 2001-11-09 2006-11-29 Scios Inc METHOD FOR TREATING CYSTIC FIBROSIS
US20030236277A1 (en) * 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
AU2003215469A1 (en) 2002-03-28 2003-10-13 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7037913B2 (en) * 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7348337B2 (en) * 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
AU2003273608A1 (en) 2002-06-11 2003-12-22 Bristol-Myers Squibb Company Viral envelope mediated fusion assay
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
US20040063746A1 (en) 2002-07-25 2004-04-01 Alicia Regueiro-Ren Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
KR20060037442A (ko) 2003-08-14 2006-05-03 화이자 인코포레이티드 Ｈｉｖ 감염 치료용 피페라진 유도체
US20050124623A1 (en) * 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US20050215543A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7776863B2 (en) * 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US7449476B2 (en) * 2004-05-26 2008-11-11 Bristol-Myers Squibb Company Tetrahydrocarboline antiviral agents
US7087610B2 (en) * 2004-06-03 2006-08-08 Bristol-Myers Squibb Company Benzothiazole antiviral agents
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
WO2007070589A3 (en) 2007-09-27
CA2635717A1 (en) 2007-06-21
AU2006326432A1 (en) 2007-06-21
US7851476B2 (en) 2010-12-14
MY144293A (en) 2011-08-29
ZA200805063B (en) 2009-10-28
NZ568776A (en) 2011-06-30
EP1963342A2 (en) 2008-09-03
EA200801529A1 (ru) 2009-02-27
NZ592684A (en) 2012-07-27
JP5400387B2 (ja) 2014-01-29
GEP20125413B (en) 2012-03-12
CN101365708A (zh) 2009-02-11
US20070155702A1 (en) 2007-07-05
NO20082477L (no) 2008-09-05
IL191769A0 (en) 2008-12-29
WO2007070589A2 (en) 2007-06-21
KR20080077010A (ko) 2008-08-20
JP2009521414A (ja) 2009-06-04
BRPI0619851A2 (pt) 2011-10-25
IL191769A (en) 2011-08-31
AU2006326432B2 (en) 2012-07-12
EA014706B1 (ru) 2011-02-28
UA94928C2 (en) 2011-06-25

Similar Documents

Publication Publication Date Title
CN101365708B (zh) 1-苯甲酰基-4-[2-[4-甲氧基-7-(3-甲基-1h-1,2,4-三唑-1-基)-1-[(膦酰氧基)甲基]-1h-吡唑并[2,3-c]吡啶-3-基]-1,2-二氧代乙基]-哌嗪的结晶形式
TW202015698A (zh) Tlr7/tlr8抑制劑之晶型
WO2022258060A1 (zh) 一种lanifibranor的晶型及其制备方法
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN113968843A (zh) 一种环己烷甲酰胺的新晶型及其制备方法
KR20160023879A (ko) 결정질 형태의 다사티닙 염
CN104918937A (zh) 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
US7829711B2 (en) Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione
WO2022052925A1 (zh) 一种洛普替尼晶型及其制备方法
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
US9598413B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9464086B2 (en) Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US7723338B2 (en) Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
MX2008007297A (es) Formas cristalinas de 1-benzoil-4-[2-[4-metoxi-7-(3-metil-1h-1,2,4-triazol-1-il)-1-[(fosfonoxi)metil]-1h-pirrolo[2,3-c]piridin-3-il]-1,2-dioxoetil]-piperazina
CN116354956A (zh) 维利西呱晶型及其制备方法
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
WO2025067474A1 (zh) 一种含吡啶的化合物及其制备方法和用途
CN117105923A (zh) 具有高生物利用度的鲁拉西酮盐及其制法和应用
CN120344512A (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2014023027A1 (zh) 盐酸埃罗替尼多晶型物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180806

Address after: The Middlesex County

Co-patentee after: VIIV health UK fifth Ltd

Patentee after: VIIV health UK fourth Ltd

Address before: new jersey

Patentee before: Bristol-Myers Squibb Co.